Published in Clin Cancer Res on December 21, 2010
Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients (DECENDO) | NCT04212377
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Central role for interleukin-2 in type 1 diabetes. Diabetes (2012) 1.19
Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med (2013) 0.95
Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res (2014) 0.91
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation. Expert Opin Biol Ther (2011) 0.89
GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells. PLoS One (2013) 0.88
Tissue resident regulatory T cells: novel therapeutic targets for human disease. Cell Mol Immunol (2015) 0.87
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother (2013) 0.82
The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation. Biomed Res Int (2013) 0.81
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. Mol Cancer (2014) 0.79
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. Retrovirology (2016) 0.78
Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate. PLoS One (2016) 0.77
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells. J Biol Chem (2015) 0.75
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 4.64
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol (2002) 3.44
Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med (2002) 3.31
Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol (2004) 3.23
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 3.06
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res (2007) 2.80
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 2.77
Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol (2009) 2.71
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol (2008) 2.62
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res (2006) 2.61
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity (2010) 2.18
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology (2013) 2.17
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol (2008) 2.11
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med (2002) 2.07
In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res (2004) 2.06
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 2.00
N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med (2014) 1.97
Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem (2010) 1.97
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med (2011) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol (2006) 1.77
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer (2012) 1.73
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther (2010) 1.67
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol (2003) 1.61
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 1.58
Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol (2006) 1.58
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56